In order to further sustain the direct involvement of AKR1C1-3 enzymes in chemotherapy resistance, we compared the mRNA expression of additional NRF2 targets, previously involved in drug metabolism, such as the glutamate-cysteine ligase catalytic subunit (GCLC), the glutamate-cysteine ligase modifier subunit (GCLM), or the UDP-glucuronosyltransferase 1A634,35 in MRDpos vs. MRDneg T-ALL patients. Here, GCLM is linked to acute lymphoblastic leukemia.